Management of systemic vasculitis

被引:16
作者
Langford, CA [1 ]
机构
[1] NIAID, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA
来源
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY | 2001年 / 15卷 / 02期
关键词
vasculitis; arteritis; Wegener; treatment; toxicity; glucocorticoid; cytotoxic; cyclophosphamide; methotrexate;
D O I
10.1053/berh.2001.0144
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The systemic vasculitides are a wide-ranging group of diseases that are characterized by the presence of blood vessel inflammation. Despite this common feature, each type of vasculitis has a unique variety of clinical manifestations that influences its degree of disease severity and ultimately its management. Immunosuppressive therapy forms the foundation of treatment for almost all forms of systemic vasculitis. Because of this, treatment can be associated with its own risk of morbidity, or even mortality, related to specific medication side-effects or infections which occur as a result of impaired host defences. This chapter seeks to review the approach to management in selected forms of systemic vasculitis. Questions examined include the following. When should one treat systemic vasculitis! How does the nature of the disease and its severity affect treatment decisions! What are the data regarding the effectiveness of individual therapeutic regimens?.
引用
收藏
页码:281 / 297
页数:17
相关论文
共 55 条
[41]   Methotrexate use in systemic vasculitis [J].
Langford, CA ;
Sneller, MC ;
Hoffman, GS .
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 1997, 23 (04) :841-&
[42]   IMMUNOSUPPRESSIVE AND CORTICOSTEROID-THERAPY OF POLYARTERITIS NODOSA [J].
LEIB, ES ;
RESTIVO, C ;
PAULUS, HE .
AMERICAN JOURNAL OF MEDICINE, 1979, 67 (06) :941-947
[43]   New treatment strategies for systemic vasculitis: The role of intravenous immune globulin therapy [J].
Lockwood, CM .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1996, 104 :77-82
[44]   SUPPLEMENTATION WITH FOLIC-ACID DARING METHOTREXATE THERAPY FOR RHEUMATOID-ARTHRITIS - A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].
MORGAN, SL ;
BAGGOTT, JE ;
VAUGHN, WH ;
AUSTIN, JS ;
VEITCH, TA ;
LEE, JY ;
KOOPMAN, WJ ;
KRUMDIECK, CL ;
ALARCON, GS .
ANNALS OF INTERNAL MEDICINE, 1994, 121 (11) :833-841
[45]  
Nowack R, 1999, J AM SOC NEPHROL, V10, P1965
[46]   INFLUENCE OF DISEASE MANIFESTATION AND ANTINEUTROPHIL CYTOPLASMIC ANTIBODY TITER ON THE RESPONSE TO PULSE CYCLOPHOSPHAMIDE THERAPY IN PATIENTS WITH WEGENERS GRANULOMATOSIS [J].
REINHOLDKELLER, E ;
KEKOW, J ;
SCHNABEL, A ;
SCHMITT, WH ;
HELLER, M ;
BEIGEL, A ;
DUNCKER, G ;
GROSS, WL .
ARTHRITIS AND RHEUMATISM, 1994, 37 (06) :919-924
[47]  
RICHTER C, 1995, CLIN EXP IMMUNOL, V101, P2
[48]   MICROSCOPIC POLYARTERITIS - CLINICAL-FEATURES AND TREATMENT [J].
RODGERS, H ;
GUTHRIE, JA ;
BROWNJOHN, AM ;
TURNEY, JH .
POSTGRADUATE MEDICAL JOURNAL, 1989, 65 (766) :515-518
[49]  
SAVAGE COS, 1985, Q J MED, V56, P467
[50]   TAKAYASUS ARTERITIS AND ITS THERAPY [J].
SHELHAMER, JH ;
VOLKMAN, DJ ;
PARRILLO, JE ;
LAWLEY, TJ ;
JOHNSTON, MR ;
FAUCI, AS .
ANNALS OF INTERNAL MEDICINE, 1985, 103 (01) :121-126